APAP

Savara Provides Pipeline and Business Update

Retrieved on: 
Thursday, December 10, 2020
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Savara, Gratitude, APAP, the AVAIL Trial, Savara

I am grateful for the opportunity to be a part of the Savara team, said Matt Pauls, Chairman and CEO, Savara.

Key Points: 
  • I am grateful for the opportunity to be a part of the Savara team, said Matt Pauls, Chairman and CEO, Savara.
  • Finally, I am excited to continue leading Savara and look forward to working on behalf of the aPAP community while creating shareholder value.
  • We extend our gratitude to the patients and clinical trial staff who participated in AVAIL, said Badrul Chowdhury, Chief Medical Officer, Savara.
  • Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

DILIsym Plays Critical Role in Submission to State of California for Common Analgesic Carcinogenicity Risk Assessment

Retrieved on: 
Tuesday, November 10, 2020
Data management, Health, Communications, Technology, Software, Pharmaceutical, Public relations, Investor relations, Drugs, Medical specialties, Clinical medicine, Hepatotoxins, Analgesics, Antipyretics, Acetanilides, Toxicology, APAP, Paracetamol, Hepatotoxicity, California Office of Environmental Health Hazard Assessment, DILIsym Services, Inc., Simulations Plus, Inc.

Californias OEHHA is assessing whether or not the common analgesic acetaminophen (a.k.a., APAP or paracetamol) should be labeled as carcinogenic to humans.

Key Points: 
  • Californias OEHHA is assessing whether or not the common analgesic acetaminophen (a.k.a., APAP or paracetamol) should be labeled as carcinogenic to humans.
  • DILIsym modeling supports key drug development decisions by predicting potential drug-induced liver injury (DILI) risk of new drug candidates.
  • DILIsym is the product of an ongoing public-private partnership (the DILI-sim Initiative ), involving scientists from the pharmaceutical industry and academia.
  • The OEHHA review of this affordable over-the-counter drug for the possible threat of carcinogenicity is an important effort for DILIsym to play a role in through the CHPA submission.

Sleep Apnea Devices Global Market Estimated to be Worth $8,173.8 Million by 2026

Retrieved on: 
Thursday, June 4, 2020
Sleep disorders, Branches of biology, Medicine, Sleep, Sleep apnea, Polysomnography, APAP, Positive airway pressure, Central sleep apnea

According to IQ4I analysis, the Sleep apnea devices market is expected to grow at a high single digit CAGR from 2019 to 2026 to reach $8,173.8 million by 2026.

Key Points: 
  • According to IQ4I analysis, the Sleep apnea devices market is expected to grow at a high single digit CAGR from 2019 to 2026 to reach $8,173.8 million by 2026.
  • The factors such as, increase in the rate of the population suffering from sleep apnea, lifestyle changes that increase the risk of sleep apnea, increasing funding and investment in the development of sleep apnea devices are the factors driving the market, favorable reimbursement policies, technological advancements such as artificial intelligence, magnap, smart PAP devices and 3D imaging are the opportunities.
  • The threat to the Sleep apnea devices market includes a lack of awareness about sleep apnea disorder and stringent regulatory requirements for new product approvals.
  • The report covers business intelligence information such as Reimbursement scenario, funding scenario, clinical trials, supply chain, major companies product and application matrix, market share analysis of overall sleep apnea devices market, polysomnography, CPAP, APAP and BiPAP devices.

Positive Airway Pressure Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Retrieved on: 
Wednesday, May 22, 2019
Medicine, Medical specialties, Health, Sleep disorders, Intensive care medicine, Mechanical ventilation, Medical equipment, Positive airway pressure, Sleep apnea, Non-invasive ventilation, APAP, CPAP

The global positive airway pressure devices market has been segmented based on product, application, end-user, and region.In terms of product, the market has been classified into CPAP, BiPAP, and APAP.

Key Points: 
  • The global positive airway pressure devices market has been segmented based on product, application, end-user, and region.In terms of product, the market has been classified into CPAP, BiPAP, and APAP.
  • Based on application, the global positive airway pressure devices market has been categorized into sleep apnea, COPD, and others.
  • All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global positive airway pressure devices market.
  • The global positive airway pressure devices market has been segmented as follows:
    Global Positive Airway Pressure Devices Market, by Product

Savara Announces Molgradex Received Fast Track Designation by FDA for Treatment of Autoimmune Pulmonary Alveolar Proteinosis

Retrieved on: 
Monday, May 6, 2019
Health, Biotechnology, Cardiology, Clinical trials, Infectious diseases, Pharmaceutical, FDA, Branches of biology, Medical specialties, Cytokines, Growth factors, Pulmonary alveolar proteinosis, Granulocyte-macrophage colony-stimulating factor, Macrophage, APAP, Fast track, Colony-stimulating factor, Savara

Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF).

Key Points: 
  • Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF).
  • Molgradex, the Companys lead product candidate, is being investigated in a pivotal Phase 3 study, called IMPALA, for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP).
  • A drug granted Fast Track designation may be eligible for Priority Review or Rolling Review of the BLA, if relevant criteria are met.
  • We are excited by this designation as it reinforces that a better treatment option is needed for people living with aPAP, said Rob Neville, Chief Executive Officer, Savara.

Dr. Jonathan Greenburg's Five Snore Experts Rock Californians To Sleep

Retrieved on: 
Monday, March 18, 2019
Sleep disorders, Branches of biology, Medicine, Clinical medicine, Snoring, Sleep apnea, Mandibular advancement splint, APAP

Those living with snoring issues and life-threatening sleep apnea can visit Greenburg and his cadre of sleep physicians in Valencia, Pasadena, Irvine, Brentwood or Encino.

Key Points: 
  • Those living with snoring issues and life-threatening sleep apnea can visit Greenburg and his cadre of sleep physicians in Valencia, Pasadena, Irvine, Brentwood or Encino.
  • NBA Hall of Famer Shaquille O'Neal sought the help of Snore Experts for his loud and often publicized snoring.
  • Snore Experts has treated over a thousand Southern California patients performing in-home sleep studies; Oral Appliance therapy, APAP/CPAP therapy, and NightLase Laser Snoring Therapy.
  • Sleep Certified is a national referral program that connects consumers with dentists who are trained specifically for snoring and sleep apnea treatment through Sleep Certified's continuing education program.

Global Sleep Apnea Devices Market by Diagnostic Devices, Therapeutic Devices 2018 and Forecast to 2023

Retrieved on: 
Tuesday, August 21, 2018
Sleep disorders, Medicine, Sleep, Health, Sleep apnea, Mandibular advancement splint, Polysomnography, APAP, Apnea

The report analyzes the sleep apnea devices market by Diagnostic Devices (Polysomnography, Respiratory Polygraphs, Pulse Oximeter and Actigraphy Devices), Therapeutic Devices ( CPAP, APAP, Bi-PAP, ASV, Facial Interfaces and Oral Appliances) and By End User (Hospitals/ Sleep Laboratories and Homecare/ Individual Use).

Key Points: 
  • The report analyzes the sleep apnea devices market by Diagnostic Devices (Polysomnography, Respiratory Polygraphs, Pulse Oximeter and Actigraphy Devices), Therapeutic Devices ( CPAP, APAP, Bi-PAP, ASV, Facial Interfaces and Oral Appliances) and By End User (Hospitals/ Sleep Laboratories and Homecare/ Individual Use).
  • Amongst the regions, North America accounts for the largest regional share in the global sleep apnea devices market in 2018.
  • Besides, the report also identifies and analyses the emerging trends along with major drivers, and challenges in the global sleep apnea devices market.
  • Global Sleep Apnea Devices Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
    Regional Markets - North America, Europe, Asia-Pacific and Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)
    Country Analysis - U.S, Canada, Mexico, Germany, France, U.K, Japan, China, Japan, India, Australia and Brazil (Actual Period: 2013-2017, Forecast Period: 2018-2023)
    Sleep Apnea Devices Market - Sizing, Growth, Forecast
    Analysis By Type - Diagnostic Devices and Therapeutic Devices.

Sleep Apnea Devices Market Worth 6.49 Billion USD by 2023

Retrieved on: 
Friday, April 20, 2018
Sleep disorders, Medicine, Health, Sleep apnea, Clinical medicine, ResMed, Mandibular advancement splint, Fisher & Paykel Healthcare, APAP, Central sleep apnea

According to a new market research report "Sleep Apnea Devices Market by Type, (Therapeutic (CPAP, APAP, Masks, ASV, Oral Appliances, Mandibular Advancement Device), Diagnostic (PSG, Oximeter)), End User (Sleep Laboratories & Hospitals, Home Care/Individuals) - Global Forecasts to 2023", published by MarketsandMarkets, the market is projected to reach USD 6.49 Billion by 2023 from an estimated USD 4.44 Billion in 2018, at a CAGR of 7.8%.

Key Points: 
  • According to a new market research report "Sleep Apnea Devices Market by Type, (Therapeutic (CPAP, APAP, Masks, ASV, Oral Appliances, Mandibular Advancement Device), Diagnostic (PSG, Oximeter)), End User (Sleep Laboratories & Hospitals, Home Care/Individuals) - Global Forecasts to 2023", published by MarketsandMarkets, the market is projected to reach USD 6.49 Billion by 2023 from an estimated USD 4.44 Billion in 2018, at a CAGR of 7.8%.
  • The major end users of sleep apnea devices include sleep laboratories & hospitals and home care/individuals.
  • North America is expected to account for the largest share of the Sleep Apnea Devices Market in 2018, followed by Europe.
  • ResMed (US), Koninklijke Philips (Netherlands), and Fisher & Paykel Healthcare (New Zealand) are the key players in the Sleep Apnea Devices Market.